MENU
+Compare
GILD
Stock ticker: NASDAQ
AS OF
Sep 9, 04:59 PM (EDT)
Price
$115.76
Change
-$0.12 (-0.10%)
Capitalization
143.64B

GILD stock forecast, quote, news & analysis

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more

Industry: #Biotechnology
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GILD showed earnings on August 07, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for GILD with price predictions
Sep 08, 2025

GILD sees its Stochastic Oscillator recovers from oversold territory

On September 05, 2025, the Stochastic Oscillator for GILD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 08, 2025. You may want to consider a long position or call options on GILD as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

GILD moved above its 50-day moving average on September 05, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 285 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on August 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GILD broke above its upper Bollinger Band on August 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.299) is normal, around the industry mean (9.491). P/E Ratio (22.968) is within average values for comparable stocks, (24.040). Projected Growth (PEG Ratio) (0.218) is also within normal values, averaging (1.790). Dividend Yield (0.027) settles around the average of (0.028) among similar stocks. P/S Ratio (5.053) is also within normal values, averaging (3.462).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

GILD is expected to pay dividends on September 29, 2025

Gilead Sciences GILD Stock Dividends
A dividend of $0.79 per share will be paid with a record date of September 29, 2025, and an ex-dividend date of September 15, 2025. The last dividend of $0.79 was paid on June 27. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 90.08B. The market cap for tickers in the group ranges from 72.83K to 672.89B. LLY holds the highest valuation in this group at 672.89B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 14%. SCLX experienced the highest price growth at 35%, while PTKFF experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 70
Price Growth Rating: 53
SMR Rating: 61
Profit Risk Rating: 78
Seasonality Score: -35 (-100 ... +100)
View a ticker or compare two or three
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
18000
Web
https://www.gilead.com